Home » Topics » Regulatory » EMA

EMA
RSS

GlaxoSmithKline withdraws MAA for Bosatria

Aug. 3, 2009

European CHMP recommends marketing authorization for Tigenix's ChondroCelect

July 2, 2009

CHMP adopts positive opinion for Otsuka's Samsca in hyponatremia

June 12, 2009

CHMP recommends granting of marketing authorization for Orphan Europe's Vedrop

June 11, 2009

EMEA provides information on possible interaction between clopidogrel and PPIs

June 9, 2009

Sepracor withdraws marketing authorization application for Lunivia (eszopiclone)

May 19, 2009

The European Commission withdraws marketing authorization for Velosulin

April 20, 2009

CHMP recommends marketing authorization for Astellas' Modigraf in transplant rejection

March 24, 2009

CHMP recommends marketing authorization for HRA's emergency contraceptive ellaOne

March 24, 2009

Bristol-Myers Squibb withdraws marketing authorization application for Ixempra

March 23, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 6, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...